Mainstream

Cytokinetics announces primary results from maple hcm presented at the european society of cardiology congress 2025 and published in the new england journal of medicine

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol

Primary Endpoint Result Consistent Across All Prespecified Subgroups

Company…Read More

You might also be interested in reading Traders split over whether Lighter’s LIT clears $3 billion FDV after launch.

August 30, 2025
In Mainstream